Front Matter (PDF) - Investigative Ophthalmology & Visual Science

MAY 1977 Vol. 16/5
National Eye Institute
Pathology Symposium—Part II
Tso and Shin
Buzneyet al.
Rodrigues et al.
Irvine et al.
Hamming et al.
Foos
Anderson and Hendrickson
Minckler et al.
Henkind et al.
Wallow and Engerman
Cogan and Yee
Hendrickson et al.
investigative
ophthalmology
&.visual science
A Journal of Clinical and Basic Research
Official Publication of the Association for
Research in Vision and Ophthalmology
Macular edema, lens extraction, 381
AR in retinal mural cells, 392
Biogenic amines, uveal melanomas, 396
Retinal neoplasia and dysplasia. II, 403
Hyaloid vasculature infrastructure, 408
Vitreoretinal juncture, 416
ICP, rapid axonal transport, 423
Axoplasmic transport, elevated IOP, 426
Optic nerve transection in cats. II, 442
Retinal blood vessels in diabetes, 447
Myelin intrusion in nerve head, 461
Visual acuity, behavior of deprived monkeys, 469
The C.V. Mosby Company
IOVSDA 16 (5) 381-474 (1977)

Though it stands only 7.5 cen
meters, Pred ForteJ" (prednisoloi
acetate 1.0%) measures tall amor
ocular steroids.
In studies comparing Pred For1
with dexamethasone phosphate
dexamethasone alcohol and prec
nisolone phosphate, Pred Fort1
emerged the undisputed ruler ir
terms of anti-inflammatory activity
In these studies by Leibowitz
et al. (using rabbit corneas with
the epithelium intact) Pred Forte
exhibited 25% more anti-inflammatory
activity than the closest
steroid, dexamethasone alcohol?
Pred Forte achieved more than
twice the corneal concentrations of
the other steroids tested in the
inflamed rabbit eyes with epithe- - ie
1
lium intact. And further, Pred Forte ; I
achieved significant concentra- -5
-/
tions in the aqueous humor? 5 ' I
Pred Wrte performs both in &
the lab and, more important, 5
on the real firing line: in your
patient's eyes.
Pred Forte, the ocular steroid
with the clinical record. Perhaps
that's why ophthalmologists
believe in Pred Forte and pre-
scribe it most.
When you see severe ocular
inflammation, remember the
"ruler": Pred Forte.
(prednisolone acetate) 1%
the steroid others are
measured against.
I
,
Pred Fortex Iprednis~~lnne acetate) 1% Sterile Ophthalmic
Suspension. INDICATIONS Fnr steroid responsive inflammation
of the palpebral and bulbar conjunctiva, cornea and
anterior segment of the globe. CONTRAINDICATIONS
Acute untreated purulent wular infections. acute superficial
herpes simplex (dendritic kerat~tis). vaccinia, varicella and
most 11ther viral diseases of the cornea and conjunctiva. (~ular
tuberculosis,and fungal diseasesof the eye,and sensitivity to
any mnipments of the formulatron. WARNINGS 1. In th~se
diseases causmg thinning of the cornea, perforation has been
reported with the use of topical steroids. 2. Since PRED
FORTEx contains no antimicrobial, if infection is present
appropriate measures must be taken to a~unteract the orga.
nisms ~nvolved. 3. Acute purulent infections of the eye
may be masked or enhanced by the use of topical steroids.
4. Use II~ sten~~d medication in the presence of stn~mal hews
simplex requlres caution and should be followed by freqwnt
mandatnry slit-lamp microscopy. 5. As fungal infections of
, the a)rnea have been reported coincidentally with longterm
I local stemid applications, fungal invasion may be suspected
$ in any persistent ameal ulcelation where a stemid has been
used. or is in use. 6. Use of topical a~rtjcnsteroids may cause
increased intrawular pressure in certain individuals. This
may result in damage to the optic nerve with defects in the
3 visual fields. It is advisable that the intrawular pressure
be checked frequently. 7. Use in Pregnancy -Safety of
3 intensive or protracted use of topical steroids during
pregnancy has mt been substantiated. PRECAUTIONS
Pmtenor subapsular cataract formation has been rep~nd
after heavy or protracted use of topical ophthalmic cnr.
ticr~steroids. Patients with histories of herpes simplex
keratitis sh~~uld be treated with caution. ADVERSE
REACTIONS Increased intraocular pressure. with optic
nerve damage, defects in the visual fields. A h ptiterior
subcapsularcataract formation, secondary (rular mfections
fnmi fungi or viruses Ilkrated fn~m ocular tissues.
and perfi~rat~on of the globe when used in ctmdit~c~ns
where there is thinnmg of the cornea or dera. Systeniic
side effects niay mur with extenswe use of stero~ds.
DOSAGE AND ADMINISTRATION 1 to 2
drnps instilled into the conjunctival sac two tu four
times daily. During the initial 24 to 48 hours the dosage
may be safely increased t11 2 drops every hour. Care
should be taken not 10 disamtinue therapy prematurely.
REFERENCE NOTES: I. Lcihmitz. H. M, and Kupfcmfan.
A. Bioorw~kbility and Iht~rapcallc. vfjfrrliruncss
of l~~picallv ad~winistrn.d rartioatrn,iils. Trans
An1 Acad Ophthalnlrd Ot~rla~ynpl N (11: 00 iH.@
XX. 1.V7.5. b Ihiil 3. /hid
A&WN Iruine. Caiifarnia

Improve your skills
in the use of fluorescein angiography
and photocoagulation
with this
superbly illustrated atlas
j~+ New 2nd Edition! ^ ^
Stereoscopic Atlas
of
Macular Diseases
For pertinent, practical information on diagnosis and management of
macular diseases, consult this magnificently illustrated new edition. Dr.
Gass correlates appearance with fluorescein angiographic findings and,
when available, histopathology. He makes use of black arid white photographs,
stereo fundus photographs in full color (19 stereo reels—4 new
to this edition); fluorescein angiograms, photomicrographs; and schematic
drawings to elucidate all textual material. Virtually a new book, this edition
has been revised and expanded to provide the most comprehensive
treatise available on macular diseases.
By J. Donald M. Gass, M.D. April, 1977. 412 pages plus FM I-XII,
8'/2" x 11", 951 illustrations plus 121 views in 19 stereo reels in color;
12 views in black and white. (Viewer not included) Price, $65.00.
ORDER BY PHONE: Call (800) 325-4177 ext. 10. In Missouri call collect—(314)
872-8370 ext. 10. 9 am to 5 pm (CDT), Monday through Friday.
MO5BV
TIMES MIRROR
THE C. V MDSBY COMPANY
11830 WESTUNE INDUSTRIAL DRIVE
ST. LOUIS MISSOURI 63141

Now, Iris fluorescein photography. From the developers
of fundus fluorescein photography. From Zeiss.
Another Zeiss First. We were first to bring you an instrument
for fluorescein angiography of the ocular fundus. Now
we have developed a slit lamp accessory for fluorescein angiography
of the iris. Easily attached to the Zeiss Slit Lamps
100/16 or 125/16 or to the Photo Slit Lamp, this special illuminator
with flash tube, ignition unit and power supply lets you
utilize one of the newest diagnostic techniques in ophthalmology.
Use one power supply for two instruments ... If you
already have a Zeiss Slit Lamp or Photo Slit Lamp and a Zeiss
Fundus Camera with Fundus Flash 2 or Power Supply 260, all
you need to do both iris and fundus fluorescein photography are
the illuminator and a switchbox. Simple. Easy to operate. And,
since Zeiss Optics are the world's greatest optics, you are assured
of excellent photographs.
For photography of the anterior segment of the eye.
Not only is iris fluorescein photography valuable for diagnosis
of disorders of the iris, but it has been used to validate a confirmative
diagnosis of diabetes, Iris fluorescein photography is
expected to become one of the most sophisticated diagnostic
techniques in medicine.
Send for more information. Write: Carl Zeiss, Inc.,
444 Fifth Avenue, New York, N. Y. 10018. Or call (212)
730-4400. In Canada: Carl Zeiss Canada Ltd., 45 Valleybrook
Drive, Don Mills, Canada M3B 2S6. Or call (416) 449-4660.
Nationwide service.
BRANCH OFFICES: BOSTON, CHICAGO, COLUMBUS, HOUSTON, LOS ANGELES, SAN FRANCISCO, WASHINGTON, D. C.
Iris Fluorescein Study, photographed by the
Ophthalmic Photo Unit, New York Medical College, New York City.
Fiuorescein angiogram of a diabetic retinopathy,
revealing a gross vasculopathy in micro and macro vessels.
THE GREAT NAME IN OPTICS

prescribe
PE OPHTHdLmiCS
by color coded vials
PINK YELLOW LAVENDER GREEN BLUE
Rx, instructions and dosage are simplified
to increase patient compliance.
Vz % (free base) epinephrine with each
strength of pilocarpine.
15cc vials—dated to assure fresh potent
medication —no refrigeration required.
DCPERSON & COVEY ING
CLENDALE, CALIFORNIA 91201 U.S.A.

3 you see abwe can
rgk conjunctivitis.
I you see below
----- of it.
NW AltlslOtEAm
Formulated with your allergic conjunctivitis*
patient in mind. AlbalonA clears the congestion
with naphazoline HCI; calms the discomforting
itch with antazoline. And AlbalonA is the only
antihistamine-decongestant in an artificial tear
vehicle: Liquifilm? (polyvinyl alcohol 1.4%). Unique
Liquifilm protects against iatrogenic dry eye; in
contrast, aqueous vehicles can cause dry eye.
That's how Albalon-A does it all faster and
more effectively than either active ingredient alone?
*Tha drug has been evaluated as possrbly effectwe for ths mdicatron
See full prescnbrng rnfonnahon
The anti-drying, antihistamine
DKCRPWN A stenle ophthalmic solubon having the following composltlon:
naphazoline HCI . . .0.05%, antazoline phosphate .0.5%.
with: LiqufilmO Ipd/vinyl akohol) 1.4%; benzalkonium chlonde .ON%;
edetate dkodium: odwinvl mlidone: sodium chlonde: sodium ace
tate, anhvdruus: ac&.ac~d and/orsodih hvdroxlde d needed to adjust
the DH MTlON AlbalonA comb~nes the efkcts of Me antihlstamme.
antazoline. and the decongestant naphazoline.
and/or other informabon. FDA has classified me indications as fol-
lows "PoaibK' effeXiw For rdief of ocular initation and/or con-
gestion of for the treatment of allergic. inflammatow. y. inkcticus
ocular conditions Final classification of the lea-thaneffective indi-
cation requires further investigation.
COlYrrUmDKllTlOlYS M/pwsensiWlW to one or more of the comw
nenb of ths weparation WING Do not use in presence of nam angle glaucoma. The prmrahon should be vsed onlv
wth caution In Me wesence of hvcettemlon, cardlac lrreeularities w
hyDerg)ycemla (d~abetes) To prevent mntamlnabng the dm&?r bp and
solution, care should be taken not to touch the evellds or surrounding
area mth the dropper bp of Me bottle Keep bottle Ughtb closed when
not In use Protect from hght ADVERSE REACTIONS The followng
advene reactions mav occur: Puoilla~ dilation. increase in intaocular
preaure. Nstemlc effects due to absorphon 11 e. hypertenuon, cardac
~mulanbes hwfgkem~al DOSAGE One or two d w lnstrlled In each
eve evecy 3 or 4 hwn or less frequentb as required to relieve mptorns
W SUPPUED 15 ml droooerdo olasdc dro~m bdtles On orescnw
tion only.
REFERENCES
Miller. J and \hMf. E H Antazolme phosphate and Wazollne hydrochloride.
wnglv and In combmanon for the mtrnent of alergerpr coryunct~bs
- a contmlled double- blind cl~nlcal ma1 Ann Albg 35 81-85.1975

For uninterrupted control of I.O.R
...never more than one or two instillations
Page 8
Scanning electron microscopy of
primate trabecular meshwork (X300):
Viewed here is Schlemm's canal
along with uveal and corneoscleral
meshwork. (Photo courtesy
Douglas R. Anderson, M.D.]
This area is the site of the prime
pathologic changes which are
responsible for glaucoma and the
focus of most of the medical
procedures for treatment of the disease.

Because PHOSPHOLINE IODIDE is long-acting, it can help provide
uninterrupted control of intraocular pressure in chronic sinnple (open-angle)
glaucoma or glaucoma secondary to aphakia. Just one or, at most,
two instillations of PHOSPHOLINE IODIDE [one at bedtime, and, if necessary,
one in the morning) are generally needed.
Although PHOSPHOLINE IODIDE is longer-acting than other miotics,
it is not more potent. With four concentrations available, it offers a high degree of
dosage flexibility for uninterrupted control of intraocular pressure... used alone
or in combination with other medication.
When starting PHOSPHOLINE IODIDE therapy, 0.03%-the lowest strength -
is the logical choice. If strengths of 0.06%, 0.125%, or 0.25% are required,
the initial use of the 0.03% will be helpful in smoothing the transition.
PHOSPHOLINE IODIDE* EESKSft
(echothiophate iodide for ophthalmic solution)
See next page ol advertisement for prescribing mformatio
Page 9

PHOSPHOLINE IODIDE
®
(echothiophate iodide)
in the management of
chronic simple (open-angle)
glaucoma or glaucoma
secondary to aphakia
BRIEF SUMMARY
(For lull prescribing information, see package circular.)
PHOSPHOLINE IODIDE'
(ECHOTHIOPHATE IODIDE FOR OPHTHALMIC SOLUTION)
PHOSPHOLINE IODIDE is a long-acting cholinesterase inhibitor
for topical use.
Indications: Glaucoma-Chronic open-angle glaucoma. Subacute
or chronic angle-closure glaucoma after iridectomy or
where surgery is refused or contraindicated. Certain non-uveitic
secondary types of glaucoma, especially glaucoma following
cataract surgery.
Accommodative esotropia-Concomitant esotropias with a
significant accommodative component.
Contraindications: 1. Active uveal inflammation.
2. Most cases of angle-closure glaucoma, due to the possibility
of increasing angle block.
3. Hypersensitiyity to the active or inactive ingredients.
Warnings: 1. Use in Pregnancy: Safe use of anticholinesterase
medications during pregnancy has not been established, nor
has the absence of adverse effects on the fetus or on the
respiration of the neonate.
2. Succinylcholine should be administered only with great
caution, if at all, prior to or during general anesthesia to patients
receiving anticholinesterase medication because of possible
respiratory or cardiovascular collapse.
3. Caution should be observed in treating glaucoma with
PHOSPHOLINE IODIDE in patients who are at the same time
undergoing treatment with systemic anticholinesterase medications
for myasthenia gravis, because of possible adverse
additive effects.
Precautions: 1. Gonioscopy is recommended prior to initiation
of therapy.
2. Wh6re;there is a quiescent uveitis or a history of this condition,
anticholinesterase therapy should be avoided or used
cautiously because of the intense and persistent miosis and
ciliary muscle contraction that may occur.
3. While systemic effects are infrequent, proper use of the
drug requires digital compression of the nasolacrimal ducts for
a minute or two following instillation to minimize drainage into
the nasal chamber with its extensive absorption area. The hands
should be washed immediately following instillation.
4. Temporary discontinuance of medication is necessary if
salivation, urinary incontinence, diarrhea, profuse sweating,
muscle weakness, respiratory difficulties, or cardiac irregularities
occur.
5. Patients receiving PHOSPHOLINE IODIDE who are exposed
to carbamate or organophosphate type insecticides and
pesticides (professional gardeners, farmers, workers in plants
manufacturing or formulating such products, etc.) should be
Page 10
warned of the additive systemic effects possible from absorption
of the pesticide through the respiratory tract or skin. During
periods of exposure to such pesticides, the wearing of respiratory
masks, and frequent washing and clothing changes
may be advisable.
6. Anticholinesterase drugs should be used with extreme caution,
if at all, in patients with marked vagotonia, bronchial
asthma, spastic gastrointestinal disturbances, peptic ulcer, pronounced
bradycardia and hypotension, recent myocardial infarction,
epilepsy, parkinsonism, and other disorders that may
respond adversely to vagotonic effects.
7. Anticholinesterase drugs should be employed prior to
ophthalmic surgery only as a considered risk because of the
possible occurrence of hyphema.
8. PHOSPHOLINE IODIDE (echothiophate iodide) should be
used with great caution, if at all, where there is a prior history of
retinal detachment.
Adverse Reactions: 1. Although the relationship, if any, of retinal
detachment to the administration of PHOSPHOLINE IODIDE
has not been established, retinal detachment has been reported
in a few cases during the use of PHOSPHOLINE IODIDE in
adult patients without a previous history of this disorder.
2. Stinging, burning, lacrimation, lid muscle twitching, conjunctival
and ciliary redness, browache, induced myopia with
visual blurring may occur.
3. Activation of latent iritis or uveitis may occur.
4. Iris cysts may form, and if treatment is continued, may
enlarge and obscure vision. This occurrence is more frequent
in children. The cysts usually shrink upon discontinuance of
the medication, reduction in strength of the drops or frequency
of instillation. Rarely, they may rupture or break free into the
aqueous. Regular examinations are advisable when the drug is
being prescribed for the treatment of accommodative esotropia.
5. Prolonged use may cause conjunctival thickening, obstruction
of nasolacrimal canals.
6. Lens opacities occurring in patients under anticholinesterase
therapy have been reported; routine examinations should
accompany prolonged use.
7. Paradoxical increase in intraocular pressure may follow
anticholinesterase instillation. This may be alleviated by prescribing
a sympathomimetic mydriatic such as phenylephrine.
Overdosage: Antidotes are atropine, 2 mg parenterally;
PROTOPAM" CHLORIDE (pralidoxime chloride), 25 mg per kg
intravenously; artificial respiration should be given if necessary.
How Supplied: Four potencies are available. 1.5 mg package
for dispensing 0.03% solution; 3.0 mg package for 0.06% solution;
6.25 mg package for 0.125% solution; 12.5 mg package
for 0.25% solution. Also contains potassium acetate (sodium
hydroxide or acetic acid may have been incorporated to adjust
pH during manufacturing), chlorobutanol (chloral derivative),
mannitol, boric acid and exsiccated sodium phosphate.
7630
The Ophthalmos Division
AYERST LABORATORIES
NewYork, N.Y. 10017

Page 12
, What
you ve come to expect
fromMosby
Eye signs
and symptoms
in brain tumors
references...
A New Book!
SYMPOSIUM ON RETINAL DISEASES
Based on lectures by noted ophthalmologists and
ophthalmic surgeons, this important new book is divided
into three sections: vitreous surgery; diabetic retinopathy;
and macular disease. Case presentations and round table
exchanges, centered on questions from the audience,
provide you with a comprehensive understanding of the
latest advances in this increasingly significant area.
By the New Orleans Academy of Ophthalmology; with 9 contributors.
March, 1977. 354 pages plus FM I-XIV, 6%" x 9%", 411 illustrations.
Price, $37.50.
New Volume V!
CURRENT CONCEPTS IN OPHTHALMOLOGY
This authoritative new volume is an essential reading for
every ophthalmologist interested in an up-to-date overview
of the state of the art. It synthesizes recent
developments in all areas of ophthalmology and carefully
explains new diagnostic methods and treatment techniques.
Outstanding discussions, written by prominent
researchers and clinicians, examine: management of corneal
graft complications; "exudative" senile macular
degeneration; laser treatment for glaucoma; herpetic
keratitis; and much more!
Edited by Herbert E. Kaufman, M.D. and Thorn J. Zimmerman,
M.D., Ph.D.; with 17 contributors. September, 1976. 297 pages
plus FM l-XII, 6%" x 9%", 157 illustrations. Price, $34.50.
New Volume V!
ATLAS OF DISEASES OF THE ANTERIOR SEGMENT
OF THE EYE:
The Crystalline Lens
This new volume offers you a precise, scholarly discussion
of the crystalline lens. Each chapter includes a general introduction,
details on various conditions, and a series of
case histories. Clinical black-and-white photographs, as
well as stereoscopic color views especially selected from
Dr. Donaldson's outstanding collection, illustrate each
case history. Two particularly noteworthy chapters discuss:
radiation and toxic cataracts; and iatrogenic and surgical
aspects of cataracts.
By David D. Donaldson, M.D. October, 1976. 212 pages plus FM I-
XIV, 8'/2" x 11", 129 illustrations, 112 stereoscopic views in full
color on 16 View-Master® reels and a View-Master® compact
viewer. Price, $54.50.

authoritative and up-to-date information for
practical management of various ophthalmic
disorders.
New 3rd Edition!
EYE SIGNS AND SYMPTOMS IN BRAIN TUMORS
Thoroughly updated, the new edition of this classic work offers
you definitive information on ocular signs and symptoms in
brain tumors, and precisely explains the correlation of eye signs
with the recognition and localization of tumors. You'll find new
and revised material on: eye motility and its disorders; red-free
funduscopy; electromyography and electro-oculography of the
eye muscles; and computerized axial tomography with the EMIscanner;
along with 35 new illustrations and updated references.
By Alfred. Huber, M.D. and Frederick C. Blodi, M.D. November, 1976.
3rd edition, 424 pages plus FM I-XVI, 6 3 /4" x 9%", 233 illustrations. Price,
$37.50.
CURRENT CONCEPTS OF THE VITREOUS
INCLUDING VITRECTOMY
Presenting the most current information on the vitreous, this
pioneering new book records the results of a two-day seminar
held to disseminate information and share techniques pertinent
to managing vitreous disorders. Innovative surgeons and
researchers offer in-depth examinations of: vitrectomy in
diabetes; preoperative evaluation before surgery; ultrasonic
evaluation; pars plana vitrectomy; and other topics. Stimulating
round table discussion deals with specific questions raised by
seminar participants (i.e., temporal versus nasal entry in vitrectomy,
etc.).
Edited by Kurt A. Gitter, M.D., F.A.C.S.; with 12 contributors. 1976, 290
pages plus FM I-XIV, 6%" x 9%", 271 illustrations. Price, $31.50.
New 4th Edition!
Becker-Shaffer's DIAGNOSIS
AND THERAPY OF THE GLAUCOMAS
This superb new 4th edition provides you with contemporary,
comprehensive information on the pathogenesis, diagnosis, and
management of glaucomas. It includes new material on
Tubinger perimeter; panretinal photocoagulation in the treatment
of diabetic retinopathy; and red-free filter
ophthalmoscopy of nerve fiber bundle defects. The book also
details two new drug delivery systems: soft contact lenses and
membrane controlled drugs. In addition, this revision provides
you with a stereoscopic gonioscopy supplement consisting of
three stereo reels (21 views).
By Allan E. Kolker, M.D. and John Hetherington, Jr., M.D. September,
1976. 4th edition, 526 pages plus FM I-X, 6%" x 9%", 448 illustrations and 8
color plates, and 3 stereoscopic reels. Price, $37.50.
ORDER BY PHONE!
Call (800) 325-4177 ext. 10. In Missouri call collect—
(314) 872-8370 ext. 10. 9 am to 5 pm (CDT), Monday through Friday.
MO5BV
TIMES MIRROR
THE C. V MOSBY COMPANY
1 1830 WESTLINE INDUSTRIAL DRIVE
ST LOUIS. MISSOURI 63141
A70476
Page 13

if ri:j r v
Classified
Advertisements
INVESTIGATIVE OPHTHALMOLOGY &
VISUAL SCIENCE will offer a classified
advertising section in each issue. It will list
opportunities wanted or offered and fellowships,
residencies, or internships wanted or
available. There will be two rates for these
ads, one for members of the Association for
Research in Vision and Ophthalmology and
one for other advertisers. Rates are as
follows:
ARVO members
(30 words or less)
Each additional word
Other advertisers
(30 words or less)
Each additional word
1 Time
$ 5.00
.40
$12.00
.40
3 Times
or more
$ 4.00/ad
.35
$10.00/ad
.35
Count all words, including abbreviations.
Initials and numbers count as one word
(Box 000, INVESTIGATIVE OPHTHALMOLOGY
& VISUAL SCIENCE)—counts as 7 words.
Payment must accompany insertion order.
Display ads. Set within a ruled border.
One inch minimum, $25.00 per inch. Forms
close 18th of each month preceding month
of issue.
INVESTIGATIVE OPHTHALMOLOGY
& VISUAL SCIENCE
Journal Advertising Department
The C. V. Mosby Company
11830 Westline Industrial Drive
St. Louis, Missouri 63141
Massachusetts—Crosseyed Domestic (non-
Siamese) Cat. Notice of Availability. The frequency
of Crosseyedness in the ordinary domestic
cat is about 1/400. Over the years we have developed
a strain of such cats, and now offer two
male-female pairs for further research. Acceptance
of these animals is contingent upon an
agreement to continue breeding. For further details
see Vis. Res. 17, 337 (1977) and contact
W. Richards El 0-135, Mass. Inst. of Tech., 79
Amherst St., Cambridge, Ma. 02139. Tel: 617-
253-5776.
Page 14
Editors!
Reviewers!
Authors!
For you ... a new book that
contains virtually everything
you want to know about
THE SCIENTIFIC JOURNAL:
EDITORIAL POLICIES AND
PRACTICES
Guidelines for Editors, Reviewers,
and Authors
In 1665 the first scholarly journal was published
in France. Since that time, there has
been no one source of editorial guidelines for
journal editors. This new book now provides
you with such a source.
YOU DECIDE
YOUR OWN APPROACH!
Presenting the advantages and disadvantages of
each specific decision, eminent editors offer you
various recommendations, discussions, and opinions
concerning the problems you may encounter.
The book is divided into two general sections:
editorial policies, which usually require major decisions;
and editorial practices, which involve
minor decisions, often about format or mechanical
style. You'll find essays exploring: the manuscript
reviewing system: special types of manuscripts
(abstracts, transactions, solicited manuscripts,
book reviews). You'll value chapters
which cover: information for authors: copyright;
errata; references cited; copy-editing; journal
cover; etc.
From "the purpose of scientific journals" to
"binding practices." this new book contains virtually
everything you want to know as editor,
reviewer, or author. See for yourself!
By Lois DeBakey, Ph.D. In collaboration with: Paul F.
Cranefidd, M.D., Ph.D.; Ayodhya P. Gupta, M.D.;
Franz J. Ingelfinger, M.D.; Robert J. Levine, M.D.;
Robert H. Moser, M.D.; J. Roger Porter, Ph.D.; and F.
Peter Woodford, Ph.D. August, 1976. 128 pages,
6" x 9". Price, $9.95.
Please send me on 30-day approval THE SCIENTIFIC
JOURNAL: EDITORIAL POLICIES AND PRACTICES. Price,
$9.95.
D Bill me Q Master-Charge#
• Payment enclosed
Name
Address
City
State -Zip Code
MO5BY
TIMES MIRROR
30-day approval offer
good only in continental
U.S. and Canada.
THE C. V. MOSBY COMPANY
11830 WESTLINE INOUSTRIAL DRIVE
A60513
ST. LOUIS. MISSOURI 63141

Iff
investigative ophthalmology
& visual science
A Journal of Clinical and Basic Research
Official Publication of the Association for Research in Vision and Ophthalmology
EDITOR
Herbert E. Kaufman, M.D.
Professor of Ophthalmology and Pharmacology
College of Medicine, University of Florida
Gainesville, Florida 32610
Manuscripts
Address correspondence related to manuscripts
to the Editor, Herbert E. Kaufman, M.D., Department
of Ophthalmology, College of Medicine,
University of Florida, Gainesville, Florida 32601.
Scope and selection. Investigative Ophthalmology
& Visual Science is intended to convey information
to those interested in all areas of visual research.
We welcome the submission of manuscripts describing
laboratory and clinical investigations ot
the eye and the visual processes. Papers submitted
for publication should be original and should not
be submitted for publication elsewhere. Papers submitted
by non-members of the Association for
Research in Vision and Ophthalmology will be
given equal consideration. Papers should be
written in English and contributed solely to
Investigative Ophthalmology & Visual Science.
Preference will be given to timely reports, to
manuscripts of 2,000 words or less (approximately
eight double-spaced typewritten pages), and to
reports of broadest general interest.
Statements and opinions expressed in the articles
and communications herein are those of the
author(s) and not necessarily those of the Editors)
or publisher and the Editor(s) and publisher
disclaim any responsibility or liability for
such material. Neither the Editor(s) nor the
publisher guarantee, warrant, or endorse any
product or service advertised in this publication,
nor do they guarantee any claim made by the
manufacturer of such product or service.
Style and organization. Articles should be written
so as to be easily understandable to vision researchers
in many fields. Abstracts should be as
free of jargon and specialized language as possible
and should specifically state the conclusions of the
study. All investigators should specify any direct
or indirect financial interest involved in the outcome
of any paper or study, and all sources of
support.
Submit the original and three (3) copies of
the manuscript and illustrations. Type manuscript
double-spaced on one side of the paper. The
following organization is recommended: 1. Abstract
(250 words or less orienting the problem,
describing the major observations, and stating the
principal conclusion). 2. Introduction and objective
of study (omit extensive reviews of the
literature). 3. Methods and experimental design
Editorial communications
PUBLISHER
The C. V. Mosby Company
11830 Westline Industrial Drive
St. Louis, Missouri 63141, U. S. A.
(brief but compatible with repetition of the work;
refer to published procedures by reference only).
4. Results (describe with minimum of discussion
—use such tables, photographs, and charts as
are necessary to clarify and document the text).
5. Discussion (limit to the data presented, their
significance, and their limitations; avoid unsupported
hypotheses). Avoid unusual abbreviations;
employ standard chemical or nonproprietary pharmaceutical
nomenclature. (See Style Manual for
Biological Journals, ed. 3, 1972, American Institute
of Biological Sciences, 3900 Wisconsin Ave., N.W.,
Washington, D. C. 20016.)
Key words. A list of 5 to 10 key words should
be provided on a separate sheet. A selection will
be made from these and printed at the head
of the article to facilitate indexing and retrieval
for the medical literature.
References. Restrict the bibliography to pertinent
references. Refer to them in the text by number
only, and list and number them at the end of
the manuscript in the order of their mention,
using style found in the Cumulated Index Medicus
and in the following order: 1. Journal references:
authors, title, journal, volume, page, and
year. 2. Book references: authors, title, edition,
city, year, and publisher. It is the author's responsibility
to verify each reference.
Illustrations. Results may be presented in tables
or figures, but only under exceptional circumstances
should the same data be presented in
both. Illustrations should be numbered consecutively
in Arabic, and marked lightly on the
back with figure number, author's name, and
"top." Type legends on a separate sheet. Provide
unmounted, glossy photographic prints in which
the details are clearly evident, or original illustrations
on good quality paper on which the lining
and lettering are done with India ink. A reasonable
number of halftone illustrations will be reproduced
free of cost to the author, but special
arrangements must be made with the Editor for
color plates, elaborate tables, or extra illustrations.
Reports. Special consideration for rapid review and
prompt publication will be given to Reports. These
should be written in the same format as regular
papers, including an abstract, but should be no
longer than 5 double-spaced, typewritten pages
in length; they may include up to 4 figures or
tables and no more than 10 references.
May 1977 Page 15

When
a Problem... ULTRASONIC
FRAGMENTATION (USF)
Can help!
Vitreous, 12 lens material,
and other ocular structures
can be fragmented and easily
aspirated through an ultrasonically
vibrated needle.
Equipment simplicity,versatile
applications, and small
incisions are just a few reasons
you should know more
about USF.
For more information on our
system and a listing of our
scheduled regional workshops
on Ultrasonic Fragmentation
(USF) please
write or call us toll free,
800-631-1152.
REFERENCES: 1. Girard L.J. et al TR AM ACAD OPHTH
& OTOL, Jan.-Feb. 1974, 2. Girard L.J, et al TR AM ACAD
OPHTH A OTOL, June 1976.
OPHTHALMIC
SYSTEMS
Page 16
OPHTHALMIC SYSTEMS
Division of
SPARTA INSTRUMENT CORPORATION
305 FAIRFIELD AVENUE/FAIRFIELD, NEW JERSEY 07006
Telephone: (Toll free) 800-631-1152

INTRAOCULAR SURG€RY
USING ULTRASONIC FRA3MGMATION (USF)
THREE LOCATIONS
HOUSTON Twelve Oaks Professional Building
Emphasis and Objectives: Advanced course in Ophthalmic Microsurgery,
includes Ultrasonic Fragmentation (USF) of
cataracts, vitreous, iris and associated procedures;
Intraocular Lens Implantation.
Course Director: Louis J. Girard, M.D., F.A.C.S.
Dates: July 21,22,23
Accommodations: Contact Louis J. Girard, M.D. (713) 965-0700
ORLANDO
Emphasis and Objectives:
Course Director:
Dates:
Accommodations:
MARYLAND
Emphasis and Objectives:
Course Directors:
Dates:
Accommodations:
Disney World
Develop the basic skills necessary to perform
cataract extractions and anterior vitrectomy,
using Ultrasonic Fragmentation (USF).
Frank Pollack, M.D.
May 26-27
Contemporary Resort Hotel
Mercy Hospital, Baltimore
Develop the basic skills necessary to perform
cataract extractions and anterior vitrectomy,
using Ultrasonic Fragmentation (USF).
Leeds E. Katzen, M.D.; Jay N. Parran, M.D.;
David L. Schwartzfarb, M.D.
April 23-24
Baltimore Hilton
PROGRAM
Developing micro-surgical skills, using
Ultrasonic Fragmentation (USF) and
operating microscopes. Emphasis will be
on laboratory sessions, accompanied by
faculty lectures and films.
SEMINAR FEE: $650
(Hotel reservations not included)
Ophthalmic Surgery Seminars
155 Clinton Road (P.O. Box 565), Caldwell, New Jersey 07006
PHONES: Toll Free (800) 631-1152 In New Jersey call (201) 575-8227
Page 17

I mgl isidi ngSityvo?
OAur ^
a ne^/ re\tetl ©f elf
Here's hew h 1
SJrfagle a
AM flBS^IpE?se
ptjv©*t*
designed ba's,*
Tilting
The TRC-RII
itHi tiltring facility.
Iterate fundus photography to
ontal Positioning
fture a center of rotation at the
ift F s&allows the operator to easily
rfakphotography. Newlyte"s
stereo photography.
Many©their ntant Benefits
Alfftbur TF^© J Rpl^ifis*(fnodels provide an
automatic fijlrm a]slj|afii©e*system, useful in
f luor=es®eiifi arag'&Fgpaptay Our unique new
Polaroid att&eh v ijij£eRt ('optional)
permits taking ©f tw© side-by-side^
exposures ©RI 'apsir^igle^piece of
Polaroid filim Slarndbrd features
include Spe®t